IE
CTNM

Israel Englander’s Contineum Therapeutics CTNM Stock Holding History

Israel Englander’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,200
Closed -$226K – 6551
2025
Q3 		$226K Buy
+19,200
New +$155K ﹤0.01% 5484

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Israel Englander's CTNM Position: Q2 2026 in Review

Israel Englander reduced its Contineum Therapeutics (CTNM) stake by 39% in Q2 2026, selling an estimated $7.92M and leaving 931,709 shares worth $15.3M. The position accounts for 0.01% of the portfolio, ranked #1876.

Israel Englander first reported a position in CTNM in Q2 2025 and has held it in 5 quarters since. The position peaked at $20.1M in Q1 2026. 101 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Israel Englander held 931,709 shares of Contineum Therapeutics worth $15.3M as of Q2 2026.
  • Israel Englander sold 603,740 Contineum Therapeutics shares in Q2 2026, an estimated $7.92M.
  • Contineum Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1876 holding.
  • Israel Englander first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Israel Englander's Contineum Therapeutics position peaked at $20.1M in Q1 2026.
  • 101 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.